What is the study about?

Studies have found that people with elevated levels of abnormal proteins, amyloids, in the brain may be at risk, or at the earliest stages, of Alzheimer’s disease. Gantenrumab is an investigational drug that prompts the body’s immune system to remove amyloids.

The Skyline study seeks to understand whether Gantenerumab can prevent or slow the development of the symptoms of Alzheimer’s in people who are risk for, or in the earliest stages of, the disease.

Who can take part?

We are looking for healthy people aged between 60 and 80. You will be given a blood test or a PET scan (a type of head scan) to find out if you are likely to develop Alzheimer’s in the future. If these tests show you do have a risk of developing Alzheimer’s in the future you will be invited to participate in the study. It’s expected that a high proportion of candidates will not meet the criteria for receiving Gantenerumab/placebo in the study.

What is involved?

If you meet the criteria for receiving Gantenerumab, you will be assigned to either receive Gantenerumab or a placebo (you will not know which group you are in). The drug is given by injection. Your first four doses will be given to you at our clinic at Two Bridges, Chertsey. After this, we will agree with you the best way to administer doses going forward. You will be given MRI scans and other tests throughout the study to measure any effect the drug may be having.

The study consists of three parts and will take approximately 4 years and 9 months to complete. This is split into a screening period of up to 17 weeks and a two stage treatment period of approximately 4 years. There will be a safety follow-up 16 weeks after your final week in the maintenance dosing period.

How do I find out more or get involved?

We would really like to hear from you if you fit the description above and are interested in taking part to help in the search for effective treatment to prevent or slow the symptoms of Alzheimer’s. Email research@sabp.nhs.uk or call 01372 216584 for more information